SRT-2104

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
SRT-2104
DrugBank Accession Number
DB12186
Background

SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 516.64
Monoisotopic: 516.140216385
Chemical Formula
C26H24N6O2S2
Synonyms
Not Available
External IDs
  • SRT2104

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Phenylimidazoles / 2,4,5-trisubstituted thiazoles / Thiazolecarboxamides / 2-heteroaryl carboxamides / Aralkylamines / Pyridines and derivatives / Morpholines / N-substituted imidazoles / Heteroaromatic compounds / Secondary carboxylic acid amides
show 7 more
Substituents
2,4,5-trisubstituted 1,3-thiazole / 2-heteroaryl carboxamide / 4-phenylimidazole / 5-phenylimidazole / Amine / Amino acid or derivatives / Aralkylamine / Aromatic anilide / Aromatic heteropolycyclic compound / Azacycle
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4521NR0J09
CAS number
1093403-33-8
InChI Key
LAMQVIQMVKWXOC-UHFFFAOYSA-N
InChI
InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
IUPAC Name
4-methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide
SMILES
CC1=C(SC(=N1)C1=CC=CN=C1)C(=O)NC1=CC=CC=C1C1=CN2C(CN3CCOCC3)=CSC2=N1

References

General References
Not Available
PubChem Compound
25108829
PubChem Substance
347828472
ChemSpider
28637794
ZINC
ZINC000043202455

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedOtherType 2 Diabetes Mellitus1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentType 2 Diabetes Mellitus1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
1CompletedBasic ScienceHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedBasic ScienceMuscular Atrophy1
1CompletedBasic ScienceSeptic1
1CompletedBasic ScienceType 2 Diabetes Mellitus4
1CompletedOtherPsoriasis1
1CompletedTreatmentUlcerative Colitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP3.79ALOGPS
logP3.29ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)11.2ChemAxon
pKa (Strongest Basic)5.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area84.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity163.83 m3·mol-1ChemAxon
Polarizability54.74 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:34 / Updated on June 12, 2020 16:53